CONSTANT LEVERAGE SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-07-12 pm EDT | ||
| 0.075 EUR | -7.41% |
|
| 1 month | +1.35% | ||
| 3 months | -50.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.075 | -7.41% |
| 24-07-11 | 0.081 | +8.00% |
| 24-07-10 | 0.075 | -3.85% |
| 24-07-09 | 0.078 | +8.33% |
| 24-07-08 | 0.072 | -4.00% |
Real-time Euronext Paris
Last update July 12, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 2FLMB | |
| ISIN | NLBNPNL2IDU5 |
| Date issued | 2023-09-20 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.63 € |
|---|---|
| Lowest since issue | 0.058 € |
| Spread | 0.004 € |
| Spread % | 5.19% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
- Stock Market
- Certificates
- 2FLMB Certificat
